In 2025, Ovarian Cancer Research Alliance (OCRA) invested more than $10.8 million toward scientific research—part of our $14.5 million commitment to strengthen the community through research, patient support, education and advocacy.
This year’s investment represents OCRA’s broadest scope to date, encompassing not only our renowned grant programs but also global collaborations leveraging artificial intelligence (AI) and data-driven initiatives that unite researchers, clinicians, and patients to accelerate discovery and improve outcomes.
Selected through a rigorous peer-review process led by OCRA’s Scientific Advisory Committee, OCRA’s next cohort of grantees were chosen from more than 350 letters of intent submitted by investigators from around the world. Their projects, launching in 2026, will focus on some of the most urgent priorities in ovarian cancer and gynecologic cancer research, including early detection, treatment resistance, and the development of new therapeutic strategies.
OCRA is empowering scientists to pursue ideas that will define the next era of ovarian and gynecologic cancer research,” said Audra Moran, OCRA’s President & CEO. “Each study we fund brings us closer to earlier detection, more effective treatments, and a future filled with greater hope for every person impacted by these diseases.
Since its founding, OCRA has invested more than $137 million in scientific research worldwide, making it the largest non-governmental funder of ovarian cancer research. With each new investment, OCRA continues to drive progress toward prevention, better treatments, and—ultimately—cures.
Explore OCRA’s current grantees and stay tuned to learn about studies to be funded in 2026.
